- Home
- MA vs JNJ Comparison
MA vs JNJ Comparison
Compare MA & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MA | JNJ |
|---|---|---|
| Founded | 1966 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.3B | 542.4B |
| IPO Year | 2005 | 2003 |
Fundamental Metrics
Financial Performance| Metric | MA | JNJ |
|---|---|---|
| Price | $542.57 | $252.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 20 |
| Target Price | ★ $649.19 | $238.20 |
| AVG Volume (30 Days) | 3.4M | ★ 8.0M |
| Earning Date | 04-30-2026 | 04-14-2026 |
| Dividend Yield | 0.66% | ★ 2.36% |
| EPS Growth | 18.93 | ★ 90.50 |
| EPS | ★ 4.35 | 2.14 |
| Revenue | ★ $32,791,000,000.00 | N/A |
| Revenue This Year | $16.19 | $6.63 |
| Revenue Next Year | $12.35 | $7.43 |
| P/E Ratio | $126.55 | ★ $116.66 |
| Revenue Growth | ★ 16.42 | N/A |
| 52 Week Low | $464.52 | $162.78 |
| 52 Week High | $601.77 | $269.43 |
Technical Indicators
Market Signals| Indicator | MA | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 63.94 | 54.90 |
| Support Level | $541.22 | $223.12 |
| Resistance Level | $543.65 | $269.43 |
| Average True Range (ATR) | 12.23 | 5.88 |
| MACD | 2.25 | -1.46 |
| Stochastic Oscillator | 80.33 | 32.29 |
Price Performance
Historical ComparisonAbout MA Mastercard Incorporated
Mastercard is the second-largest payment processor in the world, having processed close to $11 trillion in volume during 2025. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.